Molecular mechanisms involved in obesity-associated insulin resistance: Therapeutical approach

References

• Abel ED, Peroni O, Kim JK, Kim YB, Boss O, Hadro E, Minnemann T, Shulman GI, Kahn BB. (2001). Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 409: 729–33.
   PubMed Web of Science ®Google Scholar
• Al-Khalili L, Bouzakri K, Glund S, Lonnqvist F, Koistinen HA, Krook A. (2006). Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol Endocrinol 20:3364–75.
   PubMed Web of Science ®Google Scholar
• Arner P. (2003). The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 14: 137–45.
   PubMed Web of Science ®Google Scholar
• Axelsen M, Smith U, Eriksson JW, Taskinen MR, Jansson PA. (1999). Postprandial hypertriglyceridemia and insulin resistance in normoglycemic first-degree relatives of patients with type 2 diabetes. Ann Intern Med 131: 27–31.
   PubMed Web of Science ®Google Scholar
• Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, Hainque B. (2002). Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87: 2084–9.
   PubMed Web of Science ®Google Scholar
• Belfrage P, Fredrikson G, Nilsson NO, Stralfors P. (1981). Regulation of adipose-tissue lipolysis by phosphorylation of hormone-sensitive lipase. Int J Obes 5: 635–41.
   PubMed Web of Science ®Google Scholar
• Bento JL, Palmer ND, Mychaleckyj JC, Lange LA, Langefeld CD, Rich SS, Freedman BI, Bowden DW. (2004). Association of protein tyrosine phosphatase 1B gene polymorphisms with type 2 diabetes. Diabetes 53: 3007–3012.
   PubMed Web of Science ®Google Scholar
• Bergman RN, Mittelman SD. (1998). Central role of the adipocyte in insulin resistance. J Basic Clin Physiol Pharmacol 9: 205–21.
   PubMedGoogle Scholar
• Bouzakri K, Zierath JR. (2007). MAP4K4 gene silencing in human skeletal muscle prevents tumour necrosis factor-alpha- induced insulin resistance. J Biol Chem 282: 7783–9.
   PubMed Web of Science ®Google Scholar
• Bruemmer D, Law RE. (2005). Liver x receptors: potential novel targets in cardiovascular diseases. Curr Drug Targets Cardiovasc Haematol Disord 5: 533–40.
   PubMedGoogle Scholar
• Butler M, McKay RA, Popoff IJ, Gaarde WA, Witchell D, Murray SF. Dean NM, Bhanot S, Monia BP. (2002). Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes 51: 1028–1034.
   PubMed Web of Science ®Google Scholar
• Cao G, Liang Y, Broderick CL, Oldham BA, Beyer TP, Schmidt RJ, Zhang Y, Stayrook KR, Suen C, Otto KA, et al. (2003). Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. J Biol Chem 278:1131–6.
   PubMed Web of Science ®Google Scholar
• Carey AL, Febbraio MA. (2004). Interleukin-6 and insulin sensitivity: friend or foe? Diabetologia 47:1135–42.
   PubMed Web of Science ®Google Scholar
• Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG., Ramm G, Prelovsek O, Hohnen-Behrens C, Watt MJ, James DE, et al. (2006). Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55: 2688–97.
   PubMed Web of Science ®Google Scholar
• Chehab FF. (2008). Obesity and lipodystrophy−where do the circles intersect? Endocrinology 149:925–34.
   PubMed Web of Science ®Google Scholar
• Coppack SW, Evans RD, Fisher RM, Frayn KN, Gibbons GF, Humphreys SM, Kirk ML, Potts JL, Hockaday TD. (1992). Adipose tissue metabolism in obesity: lipase action in vivo before and after a mixed meal. Metabolism 41: 264–72.
   PubMed Web of Science ®Google Scholar
• Cozzone D, Debard C, Dif N, Ricard N, Disse E, Vouillarmet J, Rabasa-Lhoret R, Laville M, Pruneau D, Rieusset J, Lefai E, Vidal H. (2006). Activation of liver X receptors promotes lipid accumulation but does not alter insulin action in human skeletal muscle cells. Diabetologia 49: 990–99.
   PubMed Web of Science ®Google Scholar
• Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, Kuo FC, Palmer EL, Tseng YH, Doria A, Kolodny GM, Kahn CR. (2009). Identification and importance of brown adipose tissue in adult humans N Engl J Med 360:1509–17.
   PubMed Web of Science ®Google Scholar
• Dalen KT, Ulven SM, Bamberg K, Gustafsson JA, Nebb HI. (2003). Expression of the insulin-responsive glucose transporter GLUT4 in adipocytes is dependent on liver X receptor alpha. J Biol Chem 278:48283–91.
   PubMed Web of Science ®Google Scholar
• Danielsson A, Nystrom FH, Stralfors P. (2006). Phosphorylation of IRS1 at serine 307 and serine 312 in response to insulin in human adipocytes. Biochem Biophys Res Commun 342:1183–7.
   PubMed Web of Science ®Google Scholar
• de Alvaro C, Teruel T, Hernandez R, Lorenzo M. (2004). Tumour necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J Biol Chem 279:17070–78.
   PubMed Web of Science ®Google Scholar
• de Luca C and Olefsky JM. (2008). Inflammation and insulin resistance. FEBS Lett 582:97–105.
   PubMed Web of Science ®Google Scholar
• Delibegovic M, Bence KK, Mody N, Hong EG, Ko HJ, Kim JK, Kahn BB, Neel BG. (2007). Improved glucose homeostasis in mice with muscle-specific deletion of protein-tyrosine phosphatase 1B. Mol Cell Biol 27:7727–34.
   PubMed Web of Science ®Google Scholar
• Diraison F, Moulin P, Beylot M. (2003). Contribution of hepatic de novo lipogenesis and reesterification of plasma non- esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab 29:478–85.
   PubMed Web of Science ®Google Scholar
• Efanov AM, Sewing S, Bokvist K, Gromada J. (2004). Liver X receptor activation stimulates insulin secretion via modulation of glucose and lipid metabolism in pancreatic beta-cells. Diabetes 53 Suppl 3:S75–S78.
   PubMed Web of Science ®Google Scholar
• Fasshauer M, Klein J, Kralisch S, Klier M, Lossner U, Bluher M, Paschke R. (2004). Monocyte chemoattractant protein 1 expression is stimulated by growth hormone and interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 317: 598–604.
   PubMed Web of Science ®Google Scholar
• Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK. (2004). Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction Diabetes 53, 1643–1648.
   PubMed Web of Science ®Google Scholar
• Fernandez-Real JM, Pickup JC. (2008). Innate immunity, insulin resistance and type 2 diabetes. Trends Endocrinol Metab 19:10–16.
   PubMed Web of Science ®Google Scholar
• Fernandez-Veledo S, Hernandez R, Teruel T, Mas JA, Ros M, Lorenzo M. (2006a). Ceramide mediates TNF-alpha-induced insulin resistance on GLUT4 gene expression in brown adipocytes. Arch Physiol Biochem 112:13–22.
   PubMedGoogle Scholar
• Fernandez-Veledo S, Nieto-Vazquez I, de CJ, Ramos MP, Bruderlein S, Moller P, Lorenzo M. (2008). Hyperinsulinemia induces insulin resistance on glucose and lipid metabolism in a human adipocytic cell line: paracrine interaction with myocytes. J Clin Endocrinol Metab 93:2866–76.
   PubMed Web of Science ®Google Scholar
• Fernandez-Veledo S, Nieto-Vazquez I, Rondinone CM, Lorenzo M. (2006b). Liver X receptor agonists ameliorate TNFalpha-induced insulin resistance in murine brown adipocytes by downregulating protein tyrosine phosphatase-1B gene expression. Diabetologia 49:3038–48.
   PubMed Web of Science ®Google Scholar
• Fontaine-Bisson B, Wolever TM, Chiasson JL, Rabasa-Lhoret R, Maheux P, Josse RG, Leiter LA, Rodger NW, Ryan EA, El-Sohemy A. (2007). Tumour necrosis factor alpha -238G > A genotype alters postprandial plasma levels of free fatty acids in obese individuals with type 2 diabetes mellitus. Metabolism 56:649–655.
   PubMed Web of Science ®Google Scholar
• Frayn KN. (2002). Adipose tissue as a buffer for daily lipid flux. Diabetologia 45:1201–1210.
   PubMed Web of Science ®Google Scholar
• Gao Z, Zuberi A, Quon MJ, Dong Z, Ye J. (2003). Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumour necrosis factor-treated cells through targeting multiple serine kinases. J Biol Chem 278:24944–50.
   PubMed Web of Science ®Google Scholar
• Green A, Dobias SB, Walters DJ, Brasier AR. (1994). Tumour necrosis factor increases the rate of lipolysis in primary cultures of adipocytes without altering levels of hormone- sensitive lipase Endocrinology 134:2581–8.
   PubMed Web of Science ®Google Scholar
• Gual P, Le Marchand-Brustel Y, Tanti JF. (2005). Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 87:99–109.
   PubMed Web of Science ®Google Scholar
• Guerra C, Koza RA, Yamashita H, Walsh K, Kozak LP. (1998). Emergence of brown adipocytes in white fat in mice is under genetic control. Effects on body weight and adiposity. J Clin Invest 102:412–20.
   PubMed Web of Science ®Google Scholar
• Guilherme A, Virbasius JV, Puri V, Czech MP. (2008). Adipocyte dysfunctions linking obesity to insulin resistance and type 2 dabetes. Nat Rev Mol Cell Biol 9:367–77.
   PubMed Web of Science ®Google Scholar
• Gum RJ, Gaede LL, Heindel MA, Waring JF, Trevillyan JM, Zinker BA, Stark ME, Wilcox D, Jirousek MR, Rondinone CM, et al. (2003). Anti-sense protein tyrosine phosphatase 1B reverses activation of p38 mitogen-activated protein kinase in liver of ob/ob mice. Mol Endocrinol 17:1131–43.
   PubMed Web of Science ®Google Scholar
• Hernandez R, Teruel T, de Alvaro C, Lorenzo M. (2004). Rosiglitazone ameliorates insulin resistance in brown adipocytes of Wistar rats by impairing TNF-alpha induction of p38 and p42/p44 mitogen-activated protein kinases. Diabetologia 47:1615–24.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS. (2003). Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 27 Suppl 3:S53–S55.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS and Spiegelman BM. (1994). Tumour necrosis factor alpha: a key component of the obesity–diabetes link. Diabetes 43:1271–8.
   PubMed Web of Science ®Google Scholar
• Huang S and Czech MP. (2007). The GLUT4 glucose transporter. Cell Metab 5:237–52.
   PubMed Web of Science ®Google Scholar
• Jiao K, Liu H, Chen J, Tian D, Hou J, Kaye AD. (2008). Roles of plasma interleukin-6 and tumour necrosis factor-alpha and FFA and TG in the development of insulin resistance induced by high-fat diet. Cytokine 42:161–9.
   PubMed Web of Science ®Google Scholar
• Kase ET, Thoresen GH, Westerlund S, Hojlund K, Rustan AC, Gaster M. (2007). Liver X receptor antagonist reduces lipid formation and increases glucose metabolism in myotubes from lean, obese and type 2 diabetic individuals. Diabetologia 50:2171–2180.
   PubMed Web of Science ®Google Scholar
• Kase ET, Wensaas AJ, Aas V, Hojlund K, Levin K, Thoresen GH, Beck-Nielsen H, Rustan AC, Gaster M. (2005). Skeletal muscle lipid accumulation in type 2 diabetes may involve the liver X receptor pathway. Diabetes 54:1108–15.
   PubMed Web of Science ®Google Scholar
• Kern PA, Di GG, Lu T, Rassouli N, Ranganathan G. (2004). Perilipin expression in human adipose tissue is elevated with obesity. J Clin Endocrinol Metab 89:1352–8.
   PubMed Web of Science ®Google Scholar
• Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. (2001). Adipose tissue tumour necrosis factor and interleukin–6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745–51.
   PubMed Web of Science ®Google Scholar
• Kershaw EE and Flier JS. (2004). Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548–56.
   PubMed Web of Science ®Google Scholar
• Kersten S. (2001). Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep 2:282–6.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB, et al. (2004). Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53:1060–7.
   PubMed Web of Science ®Google Scholar
• Klaman LD, Boss O, Peroni OD, Kim JK, Martino JL, Zabolotny JM, Moghal N, Lubkin M, Kim YB, Sharpe AH, et al. (2000). Increased energy expenditure, decreased adiposity, tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol 20:5479–89.
   PubMed Web of Science ®Google Scholar
• Klover PJ, Clementi AH, Mooney RA. (2005). Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 146:3417–27.
   PubMed Web of Science ®Google Scholar
• Kramer DK, Al-Khalili L, Guigas B, Leng Y, Garcia-Roves PM, Krook A. (2007). Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle. J Biol Chem 282:19313–20.
   PubMed Web of Science ®Google Scholar
• Kristiansen OP and Mandrup-Poulsen T. (2005). Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 54 Suppl 2:S114–24.
   PubMed Web of Science ®Google Scholar
• Laffitte BA, Chao LC, Li J, Walczak R, Hummasti S, Joseph SB, Castrillo A, Wilpitz DC, Mangelsdorf DJ, Collins JL, et al. (2003). Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci USA 100:5419–24.
   PubMed Web of Science ®Google Scholar
• Lopez-Soriano J, Chiellini C, Maffei M, Grimaldi PA, Argiles JM. (2006). Roles of skeletal muscle and peroxisome proliferator-activated receptors in the development and treatment of obesity. Endocr Rev 27:318–29.
   PubMed Web of Science ®Google Scholar
• Lowell BB, Susulic V, Hamann A, Lawitts JA, Himms-Hagen J, Boyer BB, Kozak LP, Flier JS. (1993). Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature 366:740–42.
   PubMed Web of Science ®Google Scholar
• Lumeng CN, Bodzin JL, Saltiel AR. (2007). Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117:175–84.
   PubMed Web of Science ®Google Scholar
• Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. (1997). Subcutaneous adipose tissue releases interleukin-6, but not tumour necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82:4196–200.
   PubMed Web of Science ®Google Scholar
• Montague CT and O’Rahilly S. (2000). The perils of portliness: causes and consequences of visceral adiposity. Diabetes 49:883–8.
   PubMed Web of Science ®Google Scholar
• Nedergaard J, Bengtsson T, Cannon B. (2007). Unexpected evidence for active brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab 293:E444–52.
   PubMed Web of Science ®Google Scholar
• Nedergaard J, Golozoubova V, Matthias A, Asadi A, Jacobsson A, Cannon B. (2001). UCP1: the only protein able to mediate adaptive non-shivering thermogenesis and metabolic inefficiency. Biochim Biophys Acta 1504:82–106.
   PubMed Web of Science ®Google Scholar
• Nieto-Vazquez I, Fernandez-Veledo S, de Alvaro C, Lorenzo M. (2008). Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. Diabetes 57:3211–21.
   PubMed Web of Science ®Google Scholar
• Nieto-Vazquez I, Fernandez-Veledo S, de Alvaro C, Rondinone CM, Valverde AM, Lorenzo M. (2007). Protein-tyrosine phosphatase 1B-deficient myocytes show increased insulin sensitivity and protection against tumour necrosis factor-{alpha}-induced insulin resistance. Diabetes 56, 404–13.
   PubMed Web of Science ®Google Scholar
• Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, Hirshman MF, Rosen ED, Goodyear LJ, Gonzalez FJ, et al. (2003). Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 112:608–18.
   PubMed Web of Science ®Google Scholar
• Olefsky JM. (2000). Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 106:467–72.
   PubMed Web of Science ®Google Scholar
• Penkowa M, Keller C, Keller P, Jauffred S, Pedersen BK. (2003). Immunohistochemical detection of interleukin–6 in human skeletal muscle fibers following exercise. FASEB J 17:2166–8.
   PubMed Web of Science ®Google Scholar
• Pirola L, Johnston AM, Van OE. (2004). Modulation of insulin action. Diabetologia 47:170–184.
   PubMed Web of Science ®Google Scholar
• Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. (2005). Tumour necrosis factor- alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 54:2939–45.
   PubMed Web of Science ®Google Scholar
• Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE. (2008). Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol 153:636–45.
   PubMed Web of Science ®Google Scholar
• Ricort JM, Tanti JF, Van OE, Le Marchand-Brustel Y. (1995). Alterations in insulin signalling pathway induced by prolonged insulin treatment of 3T3–L1 adipocytes. Diabetologia 38:1148–56.
   PubMed Web of Science ®Google Scholar
• Rotter SV, Larsson, BM, Johansson A, Holmang A, Smith U. (2004). Short-term infusion of interleukin-6 does not induce insulin resistance in vivo or impair insulin signalling in rats. Diabetologia 47:1879–87.
   PubMed Web of Science ®Google Scholar
• Rotter V, Nagaev I, Smith U. (2003). Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumour necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278:45777–84.
   PubMed Web of Science ®Google Scholar
• Ruan H, Hacohen N, Golub TR, Van Parijs L, Lodish HF. (2002). Tumour necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. Diabetes 51:1319–36.
   PubMed Web of Science ®Google Scholar
• Ruderman NB, Keller C, Richard AM, Saha AK, Luo Z, Xiang X, Giralt M, Ritov VB, Menshikova EV, Kelley DE, et al. (2006). Interleukin-6 regulation of AMP-activated protein kinase: potential pole in the systemic response to exercise and prevention of the metabolic syndrome. Diabetes 55 Suppl 2:S48–54.
   PubMed Web of Science ®Google Scholar
• Ryden M, Dicker A, van Hamerlen V, Hauner H, Brunnberg M, Perbeck L, Lonnqvist F, Arner P. (2002). Mapping of early signaling events in tumour necrosis factor-alpha-mediated lipolysis in human fat cells. J Biol Chem 277:1085–1091.
   PubMed Web of Science ®Google Scholar
• Sabio G, Das M, Mora A, Zhang Z, Jun JY, Ko HJ, Barrett T, Kim JK, Davis RJ. (2008). A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 322:1539–43.
   PubMed Web of Science ®Google Scholar
• Senn JJ. (2006). Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes. J Biol Chem 281:26865–75.
   PubMed Web of Science ®Google Scholar
• Senn JJ, Klover PJ, Nowak IA, Mooney RA. (2002). Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391–9.
   PubMed Web of Science ®Google Scholar
• Serino M, Menghini R, Fiorentino L, Amoruso R, Mauriello A, Lauro D, Sbraccia P, Hribal ML, Lauro R, Federici M, (2007). Mice heterozygous for tumour necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes. Diabetes 56: 2541–6.
   PubMed Web of Science ®Google Scholar
• Smith CJ and Manganiello VC. (1989). Role of hormone-sensitive low Km cAMP phosphodiesterase in regulation of cAMP- dependent protein kinase and lipolysis in rat adipocytes. Mol Pharmacol 35:381–6.
   PubMed Web of Science ®Google Scholar
• Steensberg A, Keller C, Starkie RL, Osada T, Febbraio MA, Pedersen BK. (2002). IL-6 and TNF-alpha expression in, release from, contracting human skeletal muscle. Am J Physiol Endocrinol Metab 283:E1272–8.
   PubMed Web of Science ®Google Scholar
• Steinberg GR, Michell BJ, van Denderen BJ, Watt MJ, Carey AL, Fam BC, Rikopoulos S, Proietto J, Gorgun CZ, Carling D, et al. (2006). Tumour necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab 4:465–74.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Mizuarai S, Araki H, Mashiko S, Ishihara A, Kanatani A, Itadani H, Kotani H. (2003). Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice. J Biol Chem 278:46654–60.
   PubMed Web of Science ®Google Scholar
• Tansey JT, Sztalryd C, Hlavin EM, Kimmel AR, Londos C. (2004). The central role of perilipin a in lipid metabolism and adipocyte lipolysis. IUBMB Life 56:379–85.
   PubMed Web of Science ®Google Scholar
• Teruel T, Hernandez R, Lorenzo M. (2001). Ceramide mediates insulin resistance by tumour necrosis factor-alpha in brown adipocytes by maintaining Akt in an inactive dephosphorylated state. Diabetes 50:2563–71.
   PubMed Web of Science ®Google Scholar
• Teruel T, Hernandez R, Rial E, Martin-Hidalgo A, Lorenzo M. (2005). Rosiglitazone up-regulates lipoprotein lipase, hormone-sensitive lipase and uncoupling protein-1, down- regulates insulin-induced fatty acid synthase gene expression in brown adipocytes of Wistar rats. Diabetologia 48:1180–88.
   PubMed Web of Science ®Google Scholar
• Trayhurn P and Wood IS. (2005). Signalling role of adipose tissue: adipokines and inflammation in obesity Biochem Soc Trans 33:1078–81.
   PubMed Web of Science ®Google Scholar
• Tsuchida A, Yamauchi T, Ito Y, Hada Y, Maki T, Takekawa, S, Kamon J, Kobayashi M, Suzuki R, Hara K, et al. (2004). Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 279:30817–22.
   PubMed Web of Science ®Google Scholar
• Tzeng TF, Liu IM, Cheng JT. (2005). Activation of opioid mu-receptors by loperamide to improve interleukin-6-induced inhibition of insulin signals in myoblast C2C12 cells. Diabetologia 48:1386–92.
   PubMed Web of Science ®Google Scholar
• Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. (1997). Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389:610–14.
   PubMed Web of Science ®Google Scholar
• Valverde AM, Benito M, Lorenzo M. (2005). The brown adipose cell: a model for understanding the molecular mechanisms of insulin resistance. Acta Physiol Scand 183:59–73.
   PubMedGoogle Scholar
• van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P, Hiscock N, Moller K, Saltin B, Febbraio MA, et al. (2003). Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88:3005–10.
   PubMed Web of Science ®Google Scholar
• van Harmelen V, Dicker A, Ryden M, Hauner H, Lonnqvist F, Naslund E, Arner P. (2002). Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes. Diabetes 51:2029–36.
   PubMed Web of Science ®Google Scholar
• Walcher D, Kummel A, Kehrle B, Bach H, Grub M, Durst R, Hombach V, Marx N. (2006). LXR activation reduces proinflammatory cytokine expression in human CD4-positive lymphocytes. Arterioscler Thromb Vasc Biol 26:1022–8.
   PubMed Web of Science ®Google Scholar
• Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO. (2002). Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8:75–9.
   PubMed Web of Science ®Google Scholar
• Wernstedt I, Eriksson AL, Berndtsson A, Hoffstedt J, Skrtic S, Hedner T, Hulten LM, Wiklund O, Ohlsson C, Jansson JO. (2004). A common polymorphism in the interleukin-6 gene promoter is associated with overweight. Int J Obes Relat Metab Disord 28:1272–9.
   PubMed Web of Science ®Google Scholar
• White MF. (2003). Insulin signaling in health and disease. Science 302:1710–11.
   PubMed Web of Science ®Google Scholar
• Wijesekara N, Konrad D, Eweida M, Jefferies C, Liadis N, Giacca A, Crackower M, Suzuki A, Mak TW, Kahn CR, et al. (2005). Muscle-specific Pten deletion protects against insulin resistance and diabetes. Mol Cell Biol 25:1135–45.
   PubMed Web of Science ®Google Scholar
• Wu Y, Ouyang JP, Wu K, Wang SS, Wen CY, Xia ZY. (2005). Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocin-treated diabetic rats. Br J Pharmacol 146:234–43.
   PubMed Web of Science ®Google Scholar
• Xue B, Kim YB, Lee A, Toschi E, Bonner-Weir S, Kahn CR, Neel BG, Kahn BB. (2007). Protein-tyrosine phosphatase 1B deficiency reduces insulin resistance and the diabetic phenotype in mice with polygenic insulin resistance. J Biol Chem 282:23829–40.
   PubMed Web of Science ®Google Scholar
• Zabolotny JM, Haj FG, Kim YB, Kim HJ, Shulman GI, Kim JK, Neel BG, Kahn BB. (2004). Transgenic overexpression of protein-tyrosine phosphatase 1B in muscle causes insulin resistance, but overexpression with leukocyte antigen- related phosphatase does not additively impair insulin action. J Biol Chem 279:24844–51.
   PubMed Web of Science ®Google Scholar
• Zabolotny JM, Kim YB, Welsh LA, Kershaw EE, Neel BG, Kahn BB. (2008). Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo. J Biol Chem 283: 14230–41.
   PubMed Web of Science ®Google Scholar
• Zhang J, Hupfeld CJ, Taylor SS, Olefsky JM, Tsien RY. (2005). Insulin disrupts beta-adrenergic signalling to protein kinase A in adipocytes. Nature 437:569–73.
   PubMed Web of Science ®Google Scholar
• Zhang-Gandhi CX, Drew PD. (2007). Liver X receptor and retinoid X receptor agonists inhibit inflammatory responses of microglia and astrocytes. J Neuroimmunol 183:50–59.
   PubMed Web of Science ®Google Scholar